In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 10, 2016, Pages 2831-2839

  Charrier, Cédric ^a   Salisbury, Anne Marie ^a   Savage, Victoria J ^a   Moyo, Emmanuel ^a   Forward, Henry ^a   Ooi, Nicola ^a   Cheung, Jonathan ^a   Metzger, Richard ^a   McGarry, David ^a   Walker, Rolf ^a   Cooper, Ian R ^a   Ratcliffe, Andrew J ^a   Stokes, Neil R ^a  

^a REDX PHARMA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DNA TOPOISOMERASE IV; ISOTHIAZOLONE INHIBITOR; REDX 04957; REDX 05967; REDX 05990; UNCLASSIFIED DRUG; BACTERIAL DNA; GYRASE INHIBITOR; THIAZOLE DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CYTOTOXICITY; DNA SUPERCOILING; ENTEROCOCCUS; HEPG2 CELL LINE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTATION; ANTAGONISTS AND INHIBITORS; BACTERIUM IDENTIFICATION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; EVALUATION STUDY; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEP-G2 CELL LINE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DNA, BACTERIAL; ENTEROCOCCUS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HEP G2 CELLS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; THIAZOLES; TOPOISOMERASE II INHIBITORS;

EID: 84994714146     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw228     Document Type: Article

References (49)

1. O'Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. HM Government 2014: http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis% 20for%20the%20health%20and%20wealth%20of%20nations_1.pdf.
2. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-81.
3. Boucher HW, Talbot GH, Benjamin DK Jr. et al. 10×'20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56: 1685-94.
4. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 2013; 11: 297-308.
5. Infectious Diseases Society of America. The 10×'20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-3.
6. Pew Charitable Trusts published pipeline. 2014: http://www.pewtrusts. org/en/multimedia/data-visualizations/2014/antibiotics-currently-inclinical-development.
7. O'Neill J. Securing new drugs for future generations: the pipeline of antibiotics. HM Government 2015: http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS% 20FINAL%20WEB_0.pdf.
8. Payne DJ, GwynnMN, Holmes DJ et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40.
9. Tommasi R, Brown DG, Walkup GK et al. ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov 2015; 14: 529-42.
10. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24: 71-109.
11. Singh SB. Confronting the challenges of discovery of novel antibacterial agents. Bioorg Med Chem Lett 2014; 24: 3683-9.
12. Brotz-Oesterhelt H, Sass P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol 2010; 5: 1553-79.
13. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013: http://www.cdc.gov/drugresistance/threat-report-2013/.
14. CollinF, Karkare S, Maxwell A. ExploitingbacterialDNAgyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 2011; 92: 479-97.
15. Maxwell A. DNA gyrase as a drug target. Trends Microbiol 1997; 5: 102-9.
16. Pommier Y, Leo E, Zhang H et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17: 421-33.
17. Drlica K, Hiasa H, Kerns R et al. Quinolones: action and resistance updated. Curr Top Med Chem 2009; 9: 981-98.
18. Lewis RJ, Singh OM, Smith CV et al. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J 1996; 15: 1412-20.
19. Stieger M, Angehrn P, Wohlgensinger B et al. GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin. Antimicrob Agents Chemother 1996; 40: 1060-2.
20. Bellon S, Parsons JD, Wei Y et al. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob Agents Chemother 2004; 48: 1856-64.
21. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry 2014; 53: 1565-74.
22. Ellsworth EL, Tran TP, Showalter HD et al. 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. J Med Chem 2006; 49: 6435-8.
23. Drlica K, Mustaev A, Towle TR et al. Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design. ACS Chem Biol 2014; 9: 2895-04.
24. Bax BD, Chan PF, Eggleston DS et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 2010; 466: 935-40.
25. Ratcliffe A, Cooper I, McGarry D et al. 5H-Isothiazolo[4, 5-C]pyridine-3, 4-dione or 5H-pyrazolo[4, 3-C]pyridin-3, 4-dione as antibacterial compounds. WO2015/114317.
26. Collier PJ, Ramsey AJ, Austin P et al. Growth inhibitory and biocidal activity of some isothiazolone biocides. J Appl Bacteriol 1990; 69: 569-77.
27. Williams TM. The mechanism of action of isothiazolone biocide. PP Chem 2007; 9: 14-22.
28. Savage VJ, Charrier C, Stokes NR. Antibiotic-resistant bacteria and their uses. WO2016/024098.
29. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard-Ninth Edition. M07-A9. CLSI, Wayne, PA, USA, 2012.
30. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement. M100-S22. CLSI, Wayne, PA, USA, 2012.
31. Pillai A, Ueno S, Zhang H et al. Cecropin P1 and novel nematode cecropins: a bacteria-inducible antimicrobial peptide family in the nematode Ascaris suum. Biochem J 2005; 390: 207-14.
32. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
33. Pucci MJ, Podos SD, Thanassi JA et al. In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob Agents Chemother 2011; 55: 2860-71.
34. Stokes NR, Thomaides-Brears HB, Barker S et al. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. Antimicrob Agents Chemother 2013; 57: 5977-86.
35. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000; 31 Suppl 2: S24-8.
36. Crumplin GC, Smith JT. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother 1975; 8: 251-61.
37. Noviello S, Ianniello F, Leone S et al. [Comparative in vitro bacteriostatic and bactericidal activity of levofloxacin and ciprofloxacin against urinary tract pathogens determined by MIC, MBC, Time-Kill curves and bactericidal index analysis]. Infez Med 2002; 10: 100-6.
38. Weigel LM, Steward CD, Tenover FC. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 1998; 42: 2661-7.
39. Zurfluh K, Abgottspon H, Hachler H et al. Quinolone resistance mechanisms among extended-spectrum b-lactamase (ESBL) producing Escherichia coli isolated from rivers and lakes in Switzerland. PLoS One 2014; 9: e95864.
40. Pucci MJ, Cheng J, Podos SD et al. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. Antimicrob Agents Chemother 2007; 51: 1259-67.
41. Bradbury BJ, Deshpande M, Hashimoto A et al. 4-substituted-1h-isothiazolo[ 5, 4-b][1, 4]oxazino[2, 3, 4-ij]quinoline-7, 8(2 h, 9 h)-diones and related compounds as anti-infective agents. WO2008/131415.
42. Bradbury BJ, Wiles JA, Wang Q et al. 8-methoxy-9h-isothiazolo[5, 4-b]quinoline-3, 4-diones and related compounds as anti-infective agents. WO2007/014308.
43. World Health Organisation. Antimicrobial Resistance: Global Report on Surveillance. 2014: http://www.who.int/drugresistance/documents/surveillancereport/en/.
44. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46: 1254-63.
45. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl 2: S49-56.
46. Higgins PG, StubbingsW, Wisplinghoff H et al. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and-resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother 2010; 54: 1613-5.
47. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 1995; 92: 11801-5.
48. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 1881-8.
49. Strahilevitz J, Hooper DC. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother 2005; 49: 1949-56.